Auer J, Eber B
IInd Medicine Department with Cardiology and Intensive Care, General Hospital Wels, Austria.
Curr Opin Investig Drugs. 2001 Mar;2(3):382-8.
Clinical trials have demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) significantly reduce cardiovascular-related morbidity and mortality in patients with and without coronary artery disease. Furthermore, statins are currently the most potent cholesterol-lowering drugs available. Subanalyses of the LIPID study have shown that patients suffering from unstable angina pectoris had at least the same benefit from statin therapy as did patients after myocardial infarction. Studies, recently published (AVERT or MIRACL) provide more information on the topic of therapy with statins in the early phase of acute coronary syndromes.
临床试验表明，3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂（他汀类药物）可显著降低患有和未患有冠状动脉疾病患者的心血管相关发病率和死亡率。此外，他汀类药物是目前可用的最有效的降胆固醇药物。LIPID研究的亚分析表明，不稳定型心绞痛患者从他汀类药物治疗中获得的益处至少与心肌梗死后患者相同。最近发表的研究（AVERT或MIRACL）提供了关于急性冠状动脉综合征早期他汀类药物治疗这一主题的更多信息。
